HIV vaccines: Where we are and where we are going

Lancet

Volumn 348, Issue 9032, 1996, Pages 933-937

  Haynes, Barton F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIBODY SPECIFICITY; DRUG DESIGN; IMMUNITY; PRIORITY JOURNAL; REVIEW; VIRUS MUTATION;

EID: 0030571189     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09339-7     Document Type: Review

References (47)

1. 1 Haynes BF, Pantaleo G, Fauci AS. Towards an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271: 324-28.
2. 2 Sheppard HW, Lang W, Ascher MS. The characterization of nonprogressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993; 7: 1159-66.
3. 3 Phair JP. Keynote address: variations in the natural history of HIV infection. AIDS Res Hum Retrovir 1994; 10: 883-85.
4. 4 Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-16.
5. 5 Cao Y, Qin L, Zhang L, Safrit J, No DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 201-08.
6. 6 Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994; 370: 463-67.
7. 7 Lee TH, Sheppard HW, Reis M, et al. Circulating HIV-1 infected cell burden from seroconversion to AIDS: importance of post-seroconversion viral load on disease course. J AIDS 1994; 7: 381-88.
8. 8 Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-79.
9. 9 Jurriaans S, Van Gemen B, Weverling GJ, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994; 204: 223-33.
10. 10 Sullivan N, Sun Y, Li J, et al. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995; 69: 4413-22.
11. 11 Barrow P, Lewicki H, Hahn BH, Shaw GH, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control to viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-10.
12. 12 Haynes BF. Scientific and social issues of human immunodeficiency virus vaccine development. Science 1993; 260: 1279-86.
13. 13 Rowland-Jones SL, Nixon DF, Aldhous MC, et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993; 341: 860-61.
14. 14 Bryson YJ, Pang S, Wei LS, et al. Clearance of HIV infection in a perinatally infected infants. N Engl J Med 1995; 332: 833-34.
15. 15 Rowland-Jones S, Sutton J, Ariyosh K, et al. HIV-specific cytotoxic T cells in HIV exposed but uninfected Gambian women. Nat Med 1995; 1: 59-64.
16. 16 Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995; 375: 606-11.
17. 17 Walker CM, Moody DJ, Stites DP, Levy JA, CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234: 1563-66.
18. 18 Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16. Nature 1995; 378: 563.
19. 19 Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1-α, and MIP-1-β as the major HIV suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-15.
20. 20 Feng Y, Brocter CC, Kennedy PE, Berger EA. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science 1996; 272: 872-77.
21. 21 Pincus S, Messer KG, Nara TL, et al. Temporal analysis of the antibody response to HIV envelope protein in HIV infected laboratory workers. J Clin Invest 1994; 93: 2505-13.
22. 22 Hogervorst E, Jurriaans S, de Wolf F, et al. Predictors for non- and slow progressions in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3 specific antibody levels. J Infect Dis 1995; 171: 811-21.
23. 23 Markham RB, Coberly J, Ruff AJ, et al. Maternal IgG1 and IgA antibody to V3 loop consensus sequence and maternal-infant HIV-1 transmission. Lancet 1994; 343: 1364.
24. 24 Moore JP. HIV vaccine: back to primary school. Nature 1995; 376: 115.
25. 25 Wain-Hobson S. In: Morse SSB, ed. The evolutionary biology of retroviruses. New York: Raven, 1994: 185-209.
26. 26 Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
27. 27 Ho DD. Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 102.
28. 28 Myers G, Korber B, Wain-Hobsen S, Smith RF, Pavlakis GN, eds. Human retroviruses and AIDS 1995. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos: Theoretical Biology and Biophysics Group, T-10, Mail Stop K710, Los Alamos National Laboratory, 1995: II-A-1-A-151.
29. 29 Korber B, Koup R, Walker B, Haynes B, Moore J, Myers G, eds. HIV molecular immunology database, 1995. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1995.
30. 30 Robertson DL, Hahn B, Sharp PM, et al. Recombination in AIDS viruses. J Mol Evol 1995; 40: 249-59.
31. 31 Zhang LQ, MacKenzie P, Cleland A, et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993; 67: 3345-56.
32. 32 Daniel MD, Kirchhoff F, Czajak SC, et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-41.
33. 33 Shiramizu B, Herndier BG, McGrath MS. Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas. Cancer Res 1994; 54: 2069-72.
34. 34 Baba TW, Jeong YS, Pennick D, et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267: 1820-25.
35. 35 Palker TJ, Matthews TJ, Langlois AJ, et al. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp 120 T helper cell sites and B cell neutralization epitopes. J Immunol 1989; 142: 3612-19.
36. 36 Berzofsky JA. Development of artificial vaccines against HIV using defined epitopes. FASEB J 1991; 5: 2412-18.
37. 37 Haynes BF, Yasutomi Y, Torres JV, et al. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class-I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy. Trans Assoc Am Phys 1993; 106: 33-41.
38. 38 Haynes BF, Moody MA, Heinley CS, Korber B, Millard WA, Scearce RM. HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. AIDS Res Human Retrov 1995; 11: 211-21.
39. 39 Ward F, Tuan ST, Haynes BF. Analysis of HLA frequencies in cohorts for design of HLA-based vaccines, In: Korber B, ed. Los Alamos Database 1995. Los Alamos: Los Alamos National Laboratory, 1995: IV-10-IV-16.
40. 40 Cease KB, Berzofsky JA. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Annu Rev Immunol 1994; 12: 923-89.
41. 41 Walfield AM, Li ML, Ye J, Hosein B, et al. Induction of high-titer persistent neutralizing antibodies by HIV-1 V3 Octa-branched peptides. In: Vaccines 92. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1992: 211-15.
42. 42 Nixon DF, Broliden K, Ogg G, Broliden PA. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992; 76: 515-34.
43. 43 HLA 1991. Tsuji K, Aizawa M, Sasazuki T, eds. Proceedings of the 11th International Histocompatibility Workshop and Conference. Oxford: Oxford University Press, 1992.
44. 44 Staats HF, Nichols WG, Palker TJ. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the C4/V3 peptide T 1-SP10MN(A). J Immunol (in press).
45. 45 Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268: 1612-17.
46. 46 Milich D, McLachlan A, Thorton GD, et al. Antibody production to the nucleo-capsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 1987; 329: 547-49.
47. 47 Berzofsky JA. Antigenic peptide interaction with MHC molecules: implications for the design of artificial vaccines. Sem Immunol 1991; 3: 203-16.